Switzerland Supports ‘Increasingly Important’ Decentralized Clinical Trials
A new position paper outlines several factors that sponsors must consider when planning to undertake decentralized clinical trials in Switzerland to ensure compliance with national legal and ethics requirements.
You may also be interested in...
Sponsors of three drugs have withdrawn their EU marketing authorization applications in the middle of the assessment process, including one for a bladder cancer therapy that was recently turned down in the US.
Sponsors of several new medicines are set to learn if their products are on track for pan-EU approval. One product on the list is Pfizer/Lilly’s osteoarthritis drug, tanezumab, which recently ran into trouble in the US.
Updated UK guidance describes the factors that clinical trial sponsors and investigator sites must consider when giving appointed representatives direct access to the electronic health records of participants in clinical trials to check source data.